0001104659-19-013869.txt : 20190311
0001104659-19-013869.hdr.sgml : 20190311
20190311164804
ACCESSION NUMBER: 0001104659-19-013869
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190305
FILED AS OF DATE: 20190311
DATE AS OF CHANGE: 20190311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Canute Scott A
CENTRAL INDEX KEY: 0001303416
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 19672830
MAIL ADDRESS:
STREET 1: FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
4
1
a4.xml
4
X0306
4
2019-03-05
0
0000722830
IMMUNOMEDICS INC
IMMU
0001303416
Canute Scott A
C/O IMMUNOMEDICS, INC.
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
1
0
0
0
Stock Option (right to buy)
16.96
2019-03-05
4
A
0
79818
0
A
2026-03-05
Common Stock, par value $0.01 per share
79818
79818
D
Stock Option (right to buy)
16.35
2019-03-08
4
A
0
22854
0
A
2026-03-08
Common Stock, par value $0.01 per share
22854
22854
D
The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest in full upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act.
/s/ Scott Canute
2019-03-11